AU5876399A - Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases - Google Patents
Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseasesInfo
- Publication number
- AU5876399A AU5876399A AU58763/99A AU5876399A AU5876399A AU 5876399 A AU5876399 A AU 5876399A AU 58763/99 A AU58763/99 A AU 58763/99A AU 5876399 A AU5876399 A AU 5876399A AU 5876399 A AU5876399 A AU 5876399A
- Authority
- AU
- Australia
- Prior art keywords
- integrin
- polymorphisms
- diagnosis
- treatment
- mediated diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000012355 Integrin beta1 Human genes 0.000 title 1
- 108010022222 Integrin beta1 Proteins 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 102000054765 polymorphisms of proteins Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9820341 | 1998-09-19 | ||
| GBGB9820341.7A GB9820341D0 (en) | 1998-09-19 | 1998-09-19 | Chemical compounds |
| GBGB9824500.4A GB9824500D0 (en) | 1998-11-10 | 1998-11-10 | Chemical compounds |
| GB9824500 | 1998-11-10 | ||
| PCT/GB1999/003066 WO2000017393A1 (en) | 1998-09-19 | 1999-09-15 | Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU5876399A true AU5876399A (en) | 2000-04-10 |
Family
ID=26314386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU58763/99A Abandoned AU5876399A (en) | 1998-09-19 | 1999-09-15 | Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1114183A1 (en) |
| JP (1) | JP2002526090A (en) |
| AU (1) | AU5876399A (en) |
| WO (1) | WO2000017393A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6386906B1 (en) | 1998-03-16 | 2002-05-14 | Telefonix Inc | Cord management apparatus and method |
| WO2005014853A1 (en) * | 2003-07-28 | 2005-02-17 | Universität Bremen | Comparative expression analysis for the identification of genes responsible for phenotypic differences |
| WO2008039941A2 (en) | 2006-09-27 | 2008-04-03 | The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services | Scgb3a2 as a growth factor and anti-apoptotic agent |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK162890D0 (en) * | 1990-07-06 | 1990-07-06 | Novo Nordisk As | POLYPEPTIDE |
| AU2734197A (en) * | 1996-04-19 | 1997-11-12 | Spectra Biomedical, Inc. | Correlating polymorphic forms with multiple phenotypes |
| GB9613112D0 (en) * | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
-
1999
- 1999-09-15 WO PCT/GB1999/003066 patent/WO2000017393A1/en not_active Ceased
- 1999-09-15 AU AU58763/99A patent/AU5876399A/en not_active Abandoned
- 1999-09-15 EP EP99946349A patent/EP1114183A1/en not_active Withdrawn
- 1999-09-15 JP JP2000574292A patent/JP2002526090A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000017393A1 (en) | 2000-03-30 |
| EP1114183A1 (en) | 2001-07-11 |
| JP2002526090A (en) | 2002-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2815900A (en) | Clinical and diagnostic database | |
| GB9925804D0 (en) | Biological materials and method useful in the diagnosis and treatment of diseases | |
| AU2002233643A1 (en) | Methods of treating diseases in association with decrease in the expression of AOP-1 gene or AOP-1 and remedies for the diseases | |
| AU7896100A (en) | Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance | |
| AU6583700A (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
| HUP0201997A2 (en) | Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications | |
| AU6425800A (en) | Agents for the diagnosis, prognosis and treatment of malignant diseases | |
| AU1101901A (en) | Human fgf-20 gene and gene expression products | |
| AU2729400A (en) | Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease | |
| AU5876899A (en) | Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases | |
| AU5876399A (en) | Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases | |
| ZA200203269B (en) | Nucleic acids of the human ABC1 gene and their therapeutic and diagnostic application. | |
| AU2003245858A1 (en) | Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases | |
| AU5875599A (en) | Polymorphisms in the human vcam-1 gene, suitable for diagnosis and treatment of vcam-1 ligand mediated diseases | |
| AU5611701A (en) | Agent for the diagnosis and therapy of viral diseases | |
| AU5618700A (en) | Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer | |
| GB9908059D0 (en) | Diagnosis and treatment of diseases | |
| AU5052899A (en) | Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases | |
| AU5052599A (en) | Genetic polymorphisms in the human neurokinin 2 receptor gene and their use in diagnosis and treatment of diseases | |
| AU6653698A (en) | Use of the p-ten suppressor gene in diagnosis and treatment of cancer | |
| WO2001011039A3 (en) | New sequence variants of the human 1-adrenoreceptor gene and use thereof | |
| AU2003240253A1 (en) | Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications | |
| AUPQ223999A0 (en) | Intracellular feedback controls in the diagnosis and treatment of human disease | |
| AU2003244498A1 (en) | Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications | |
| AU2352301A (en) | Gene expression in corneal diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |